Eli Lilly announces Alimta label expanded by FDA
Eli Lilly announces Alimta label expanded by FDA
Eli Lilly announces Alimta label expanded by FDA Eli Lilly announces Alimta label expanded by FDA
Eli Lilly (LLY) announced that the FDA has granted approval for a new indication for Alimta in combination with carboplatin and Keytruda for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer, or NSCLC, irrespective of PD-L1 expression status.
Under the FDA’s…
View On WordPress














